StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Earnings

Allogene Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.15
-$0.19 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Allogene Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––-$0.15Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026during market hours$4.64M–-$0.13Release
Q1 FY2026ended Mar 31, 2026May 13, 2026during market hours––-$0.18Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026during market hours––-$0.17Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours––-$0.19Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025during market hours––-$0.23Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours–––Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024during market hours––-$0.35Release
Q1 FY2024ended Mar 31, 2024May 13, 2024during market hours$22.00K-57.7%-$0.38Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Allogene Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GAAP Operating ExpensesGAAPFY2026$225.00M–NewAug 12, 2026
operating expensenon-GAAPFY2026$165.00M–NewAug 12, 2026
estimated non-cash stock-based compensation expenseFY2026$35.00M–LoweredMar 12, 2026
GAAP Operating ExpensesGAAPFY2026$225.00M–NewNov 5, 2026
GAAP Operating ExpensesGAAPFY2026$225.00M$210.00MRaisedMay 13, 2026
non-cash stock-based compensation expensenon-GAAPFY2026$35.00M–LoweredMay 13, 2026
operating cash expensenon-GAAPFY2026$165.00M–NewMay 13, 2026
operating cash expenseFY2026$150.00M–NewMar 12, 2026
operating expensenon-GAAPFY2026$165.00M–NewNov 5, 2026

Guidance history

Every forecast Allogene Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026GAAP Operating ExpensesFY2026$225.00MNew
Nov 5, 2026operating expenseFY2026$165.00MNew
Aug 12, 2026GAAP Operating ExpensesFY2026$225.00MNew
Aug 12, 2026operating expenseFY2026$165.00MNew
May 13, 2026GAAP Operating ExpensesFY2026$225.00MRaised
May 13, 2026operating cash expenseFY2026$165.00MNew
May 13, 2026non-cash stock-based compensation expenseFY2026$35.00MLowered
Mar 12, 2026operating cash expenseFY2026$150.00MNew
Mar 12, 2026estimated non-cash stock-based compensation expenseFY2026$35.00MLowered
Mar 12, 2026GAAP Operating ExpensesFY2026$210.00MNew
Nov 6, 2025decrease in cash, cash equivalents, and investmentsFY2025$150.00MNew
Nov 6, 2025GAAP Operating ExpensesFY2025$230.00MNew
Aug 13, 2025decrease in cash, cash equivalents, and investmentsFY2025$150.00MRaised
Aug 13, 2025GAAP Operating ExpensesFY2025$230.00MReaffirmed
May 13, 2025decrease in cash, cash equivalents, and investmentsFY2025$150.00MRaised
May 13, 2025non-cash stock-based compensation expenseFY2025$45.00MLowered
May 13, 2025GAAP Operating ExpensesFY2025$230.00MNew
Mar 13, 2025GAAP Operating ExpensesFY2025$250.00MNew
Mar 13, 2025decrease in cash, cash equivalents and investmentsFY2025-$170.00MNew
Nov 7, 2024GAAP Operating ExpensesFY2024$300.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Allogene Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. News
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?